Allergy Therapeutics (AGY) Competitors GBX 8.75 +0.25 (+2.94%) As of 08/8/2025 11:57 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock AGY vs. AMYT, APH, ANCR, VLG, EAH, DNL, STX, PXS, CHLL, and MXCShould you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Amryt Pharma (AMYT), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), ECO Animal Health Group (EAH), Diurnal Group (DNL), Shield Therapeutics (STX), Provexis (PXS), Chill Brands Group (CHLL), and Argent BioPharma (MXC). These companies are all part of the "drug manufacturers - specialty & generic" industry. Allergy Therapeutics vs. Its Competitors Amryt Pharma Alliance Pharma Animalcare Group Venture Life Group ECO Animal Health Group Diurnal Group Shield Therapeutics Provexis Chill Brands Group Argent BioPharma Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability. Is AMYT or AGY more profitable? Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -72.86%. Amryt Pharma's return on equity of 0.00% beat Allergy Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amryt PharmaN/A N/A N/A Allergy Therapeutics -72.86%-266.59%-34.76% Which has higher earnings and valuation, AMYT or AGY? Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmryt Pharma£210.24M0.00N/A-£33.00N/AAllergy Therapeutics£72.18M5.96-£52.59M-£1.04-8.43 Does the media refer more to AMYT or AGY? In the previous week, Allergy Therapeutics had 1 more articles in the media than Amryt Pharma. MarketBeat recorded 1 mentions for Allergy Therapeutics and 0 mentions for Amryt Pharma. Allergy Therapeutics' average media sentiment score of 0.29 beat Amryt Pharma's score of 0.00 indicating that Allergy Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Amryt Pharma Neutral Allergy Therapeutics Neutral SummaryAmryt Pharma beats Allergy Therapeutics on 5 of the 8 factors compared between the two stocks. Get Allergy Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGY vs. The Competition Export to ExcelMetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£430.07M£2.15B£5.44B£3.07BDividend Yield8.33%2.92%4.61%5.03%P/E Ratio-8.434.2729.75170.63Price / Sales5.96675.34449.48303,754.90Price / Cash3.6610.3536.4227.96Price / Book88.6710.708.184.52Net Income-£52.59M£21.15B£3.26B£5.90B7 Day Performance9.38%0.02%6.87%1.23%1 Month Performance9.38%3.22%0.99%3.62%1 Year Performance78.57%2.70%28.84%58.36% Allergy Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGYAllergy TherapeuticsN/AGBX 8.75+2.9%N/A+88.2%£430.07M£72.18M-8.43612AMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma2.0189 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 270-0.7%N/A-1.1%£185.11M£84.90M5.03220VLGVenture Life GroupN/AGBX 60.38+4.1%N/A+45.6%£76.94M£51.77M102.47165News CoverageHigh Trading VolumeEAHECO Animal Health Group3.6172 of 5 starsGBX 74.05-3.2%GBX 150+102.6%-25.1%£50.18M£89.44M47.87234News CoveragePositive NewsDNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133STXShield TherapeuticsN/AGBX 4.53+0.6%N/A+27.5%£44.69M£20.92M-1.1740,000PXSProvexisN/AGBX 0.72-3.4%N/A+19.6%£16.90M£846.98K-27.304Gap DownCHLLChill Brands GroupN/AN/AN/AN/A£10.89M£624.19K-215.007MXCArgent BioPharmaN/AN/AN/AN/A£9.65M£1.32M-13.255Gap Up Related Companies and Tools Related Companies AMYT Competitors APH Competitors ANCR Competitors VLG Competitors EAH Competitors DNL Competitors STX Competitors PXS Competitors CHLL Competitors MXC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AGY) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
